<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04258644</url>
  </required_header>
  <id_info>
    <org_study_id>BFH-CamrelizumabCombo4</org_study_id>
    <nct_id>NCT04258644</nct_id>
  </id_info>
  <brief_title>Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer</brief_title>
  <official_title>Efficacy and Safety of Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an interventional clinical trial to assess the efficacy and safety of camrelizumab in&#xD;
      combination with apatinib mesylate, paclitaxel-albumin and S-1 for translational treatment of&#xD;
      gastric cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>3 years</time_frame>
    <description>proportion of patients for whom radical resection can be achieved</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>3 years</time_frame>
    <description>objective response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DFS</measure>
    <time_frame>3 years</time_frame>
    <description>disease free survival (period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year DFS</measure>
    <time_frame>3 years</time_frame>
    <description>3-year disease free survival (rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>3 years</time_frame>
    <description>progression free survival (period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>3 years</time_frame>
    <description>overall survival (period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year OS</measure>
    <time_frame>1 year</time_frame>
    <description>1-year overall survival (rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year OS</measure>
    <time_frame>3 years</time_frame>
    <description>3-year overall survival (rate)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Camrelizumab+Apatinib+Paclitaxel-albumin+S-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Camrelizumab：D1, 200 mg ivgtt Apatinib Mesylate：D1~21, 250 mg, po qd Paclitaxel-albumin：D1&amp;D8, 100～120 mg/m2 S-1：D1~14, 60mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab+Apatinib+Paclitaxel-albumin+S-1</intervention_name>
    <description>Combination therapy of 4 drugs, 21 days for one cycle.</description>
    <arm_group_label>Camrelizumab+Apatinib+Paclitaxel-albumin+S-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age:18～70; expected survival&gt;3 months&#xD;
&#xD;
          2. pathologically diagnosed gastric cancer or esophageal-gastric-junction cancer, being&#xD;
             predominantly adenocarcinoma&#xD;
&#xD;
          3. no previous treatment of anti-cancer drugs&#xD;
&#xD;
          4. ECOG score 0~2&#xD;
&#xD;
          5. CT/MRI/PET-CT diagnosed as unresectable&#xD;
&#xD;
          6. no disfunction of major organs&#xD;
&#xD;
          7. lab results satisfy the following criteria:&#xD;
&#xD;
               -  Hb≥90g/L&#xD;
&#xD;
               -  WBC≥3.5×109/L&#xD;
&#xD;
               -  Neutrophil≥1.5×109/L&#xD;
&#xD;
               -  Plt≥100×109/L&#xD;
&#xD;
               -  ALT、AST≤2.5 upper limit (≤5 upper limit for patients with liver metastasis)&#xD;
&#xD;
               -  Tbil≤1.5 upper limit&#xD;
&#xD;
               -  serum creatinine≤1.5 upper limit&#xD;
&#xD;
        7.women at child-bearing age must be tested negative within 7 days before inclusion, and&#xD;
        must be willing to take contraception measures during treatment and within 12 weeks after&#xD;
        last dose of treatment; men must be sterilized or willing to take contraception measures&#xD;
        during treatment and within 12 weeks after last dose of treatment 8.willing to join this&#xD;
        research with hand-signed written Informed consent 9.good compliance for follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. patients with positive HER-2 test&#xD;
&#xD;
          2. with conditions that affect the absorption of oral drugs, such as inability to&#xD;
             swallow, nausea and vomiting, chronic diarrhea and intestinal obstruction&#xD;
&#xD;
          3. allergic to carrizumab for injection, apatinib mesylate, paclitaxel for injection&#xD;
             (albumin binding type) and tS-1 or relevant drug excipients; allergic to any other&#xD;
             monoclonal antibodies; cannot tolerate radiation toxicity;&#xD;
&#xD;
          4. with active autoimmune disease or autoimmune disease history, such as interstitial&#xD;
             pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis,&#xD;
             nephritis, hyperthyroidism, hypothyroidism (can be included after hormone replacement&#xD;
             therapy); patients with complete remission of childhood asthma and require no&#xD;
             intervention can be included, whereas those who need medical intervention with&#xD;
             bronchodilator cannot be included&#xD;
&#xD;
          5. with congenital or acquired immune defects, such as human immunodeficiency virus (HIV)&#xD;
             infection, active hepatitis B (HBV DNA ≥ 500 IU / ml), hepatitis C (HCV antibody&#xD;
             positive, and HCV-RNA higher than the lower detection limit of the analysis method) or&#xD;
             combined hepatitis B and hepatitis C co infection&#xD;
&#xD;
          6. immunosuppressive drugs were used within 14 days before the first use of the study&#xD;
             drug, excluding nasal spray and inhaled corticosteroids or systemic steroids in&#xD;
             physiological dose (i.e. no more than 10 mg / day of prednisolone or other&#xD;
             corticosteroids for equivalent amount);&#xD;
&#xD;
          7. inoculated live attenuated vaccine within 4 weeks before the first administration or&#xD;
             during the study period&#xD;
&#xD;
          8. severe infection (requiring intravenous drip of antibiotics, antifungal or antiviral&#xD;
             drugs) within 4 weeks before the first administration, or fever&gt; 38.5° C of unknown&#xD;
             cause during screening / before the first administration&#xD;
&#xD;
          9. known history of allogeneic organ transplantation or allogeneic hematopoietic stem&#xD;
             cell transplantation&#xD;
&#xD;
         10. objective evidence indicating previous or concurrent pulmonary fibrosis, interstitial&#xD;
             pneumonia, pneumoconiosis, radiation-induced pneumonia, drug-related pneumonia, severe&#xD;
             impairment of lung function, etc&#xD;
&#xD;
         11. patients with hypertension that cannot be restored to the normal range (systolic blood&#xD;
             pressure ≤ 140 mmHg / diastolic blood pressure ≤ 90 mmHg) after treatment with&#xD;
             antihypertensive drugs for 3 months&#xD;
&#xD;
         12. patients with uncontrolled clinical symptoms or diseases of the heart, including but&#xD;
             not limited to congestive heart failure (NYHA grade &gt; II); unstable or severe angina;&#xD;
             acute myocardial infarction within 6 months; patients with clinically significant&#xD;
             supraventricular or ventricular arrhythmia requiring clinical intervention; left&#xD;
             ventricular ejection fraction (LVEF) &lt; 50%&#xD;
&#xD;
         13. patients at risk of serious bleeding, including but not limited to severe bleeding&#xD;
             (bleeding &gt; 30 ml within 3 months), hemoptysis (bleeding &gt; 5 ml within 4 weeks), and&#xD;
             thromboembolism events (within the past 12 months)&#xD;
&#xD;
         14. with symptoms indicating Grade 2+ peripheral neuropathy&#xD;
&#xD;
         15. participating in other clinical trials, or participating in any clinical study for&#xD;
             drugs within previous 4 weeks&#xD;
&#xD;
         16. other situations that the researchers regard as not suitable for inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Deng</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhongtao Zhang</last_name>
    <phone>8618811792819</phone>
    <phone_ext>8618811792819</phone_ext>
    <email>zhongtao.z@139.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhongtao Zhang, M.D.</last_name>
      <phone>8618811792819</phone>
      <phone_ext>8618811792819</phone_ext>
      <email>zhongtao.z@139.com</email>
    </contact>
    <investigator>
      <last_name>Kai Pang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Zhongtao Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

